ARS Pharmaceuticals, Inc. - Common Stock (SPRY)

ARS Pharma Q2 2025 results: $15.7M revenue beats estimates, but stock dips amid high SG&A costs. neffy gains traction with 93% U.S. coverage and global expansion underway.

Jim Cramer recommends Union Pacific but is "getting tired of the orphan drug model." Here's what the "Mad Money" host said.

The market is filled with gapping stocks in Thursday's session. Let's discover which stocks are showing gap-ups and gap-downs.

The company is known for its first-of-a-kind drug, a nasal treatment for emergency allergic reactions.

FDA approves ARS Pharma's Neffy 1 mg, the first nasal epinephrine spray for children with severe allergies, offering a needle-free alternative to autoinjectors.

Many stocks flashed buy signals as the major indexes rose to or above key levels.

Some companies saw their shares skyrocket on preliminary reports, but others took hits.

Epinephrine is usually delivered in an auto-injector. This company is the first to win approval for a nasal spray version of it.

ALK and ARS Pharmaceuticals sign a deal giving ALK global rights to Neffy nasal spray outside key regions, targeting peak sales of around $400 million in anaphylaxis treatment.

Neffy, a nasal spray alternative to EpiPen, offers convenience and longer shelf life but faces skepticism from allergists due to limited real-world testing and potential insurance hurdles.

"FDA recently approved ARS Pharmaceuticals' neffy nasal spray for emergency allergic reactions, offering an alternative to epinephrine autoinjectors like EpiPen. Cantor sees strong market potential and forecasts $1.2 billion in peak sales by 2031.